T he most widely used second-line therapy for Helicobacter pylori eradication is quadruple therapy, consisting of a proton pump inhibitor (PPI), a bismuth salt, metronidazole, and tetracycline, as recommended by the Maastricht 3-2005 and second Asian Pacific Consensus Report. [1, 2] However, bismuth salts are not available worldwide anymore. Alternative second-line therapies with a good treatment report card are still in demand. Antibiotic resistance is one of the important factors in patients' non-responsiveness to initial treatment. [3] Usually, it is not suggested to repeat the same regimens when considering a second-line treatment for H. pylori.
Fluoroquinolone-containing second-line therapy has emerged to be an encouraging strategy for eradication failures owing to the remarkable in vitro activity against H. pylori. [5] [6] [7] [8] [9] Besides, levofloxacin-containing triple therapy has the advantage of being good orally absorptive and well tolerated antimicrobial drugs. Moreover, the synergistic effect of quinolone and PPIs on the strains of H. pylori enhanced this effect. [6, 10] Unfortunately, the existing Taiwanese reports on fluoroquinolone-containing second-line therapy have mentioned unacceptable eradication rates of less than 80%. [11] [12] [13] The main drawback in these reports could be the short treatment duration with only a 7-day course. [11] [12] [13] [14] [15] Many physicians, especially local medical doctors, still prescribe 7-day regimens. We, therefore, conducted this retrospective study to determine the appropriateness of 7-day levofloxacin/amoxicillin/PPI regimen as second-line therapy.
METHODS

Patients and study design
Sixty-one consecutive H. pylori-infected outpatients of at least 18 years of age with endoscopically proven peptic ulcer diseases or gastritis and who failed first-line eradication therapies with standard triple regimens (PPI twice daily, 500 mg of clarithromycin twice daily, and 1 g of amoxicillin twice daily) were enrolled. Criteria for exclusion included (a) ingestion of antibiotics, bismuth, or PPIs within 4 weeks before; (b) use of nonsteroidal anti-inflammatory drugs within 4 weeks before; (c) patients with allergic history to the medications used; (d) patients with previous gastric surgery; (e) coexistence of serious concomitant illness (e.g., decompensated liver cirrhosis, uremia); (f) pregnant women; and (g) incomplete chart recordings.
Treatment allocation
These H. pylori-infected outpatients who failed first-line eradication therapies were treated with levofloxacin-containing triple therapy (40 mg esomeprazole twice daily, 1 g of amoxicillin twice daily, and 500 mg of levofloxacin once daily) for 7 days. In all these patients who received anti-H. pylori eradication treatment, the patients were asked to return in the 2 nd week to assess drug compliance and adverse events, as per our policy. Patients with peptic ulcers in initial endoscopy received an additional 3 weeks of esomeprazole 40 mg orally once daily, while patients with gastritis only took 3 weeks of antacid following eradication therapy. To assess eradication efficacy, repeated endoscopy with rapid urease test and histological examination was performed at 8 weeks after the completion of anti-H. pylori therapy. For patients who refused to undergo follow-up endoscopy, urea breath test was used to confirm the H. pylori status. The absence of H. pylori after a previous eradication therapy was defined as (1) negative results of both rapid urease test and histology or (2) a negative result of urea breath test at 8 weeks. A double-check of urea breath test at 16 weeks was performed for all the participants whose infection were eradicated to avoid possible bias. The technicians who performed the H. pylori tests (rapid urease test and urea breath test) or filled in the questionnaires, as well as the pathologists were blinded to the eradication regimens that the patients received. This study was approved by both the Institutional Review Board and the Ethics Committee of Chang Gung Memorial Hospital (IRB101-3169B).
Follow-up for adverse events and compliance
Since only those patients who were registered as receiving anti-H. pylori treatments were enrolled, a complete medical history and demographic data of each patient was available, including age, sex, and medical history, history of smoking, alcohol, and coffee or tea consumption. Smoking was defined as using one pack or more of cigarettes per week. Adverse events such as abdominal pain, diarrhea, constipation, dizziness, taste perversion, headache, anorexia, nausea, vomiting, and skin rash that interfered with patient's quality of life were recorded. Poor compliance was defined as taking less than 80% of the total medication. [16] 
Outcomes
The primary endpoint of our study was successful eradication of H. pylori. Additional analyses were conducted on the adverse events during therapies.
Diagnosis of H. pylori infection
Rapid urease test
One gastric antrum specimen and one corpus biopsy specimen each were collected during endoscopy for testing by using a commercial rapid urease test (Pronto Dry; Medical Instrument Corp., Solothurn, Switzerland). [17] The results of the rapid urease test were interpreted as positive if the color of the gel turned pink or red 1 h after examination at room temperature.
Urea breath test
The urea breath test was performed at 8 weeks in accordance with our previous studies.
[ 18] The cut-off value was set at 4.8% of d13CO2. Staffs who performed the tests were blinded to the H. pylori status.
Culture and antimicrobial resistance
Two antral gastric and corpus biopsy specimens each were obtained for isolation of H. pylori. H. pylori culture was obtained by rubbing the specimens on the surface of a Campy-BAP agar plate [Brucella agar (Difco, Sparks, MD, USA) + IsoVitalex (Gibco, Grand Island, NY, USA) +10% whole sheep blood]. Then, they were incubated at 37°C under microaerobic conditions (5% O 2 , 10% CO 2 , and 85% N 2 ) for 4-5 days. The results were considered positive if one or more colonies of gram-negative bacilli with positive oxidase, catalase, and urease tests were found. The H. pylori strains were tested for tetracycline, metronidazole, and clarithromycin susceptibility using the E-test (AB Biodisk, Solna, Sweden). H. pylori strains with a minimal inhibitory concentration (MIC) values >4 mg/ml, 8 mg/ml, and >1 mg/ml were considered to be resistant to tetracycline, metronidazole, and clarithromycin, respectively.
Statistical analysis
Chi-square test with or without Yates correction for continuity and Fisher's exact test were used when appropriate to compare the treatment outcome and host factors using SPSS program (version 10.1, Chicago, IL, USA). A P value less than 0.05 was considered statistically significant.
RESULTS
Characteristics of the study groups
A total of 61 H. pylori-infected patients who failed first-line therapy were enrolled in our study. The subjects were all included in the intention-to-treat (ITT) analysis for H. pylori eradication. The clinical characteristics of patients at entry are summarized in Table 1 . Among the 61 subjects, three patients discontinued medication because of poor compliance to adverse events, and eventually, 58 patients were excluded from per-protocol (PP) analysis for H. pylori eradication and they finished all the medications. The eradication rates were 78.7% in the ITT analysis and 81% in the PP analysis [ Table 2 ].
Adverse events, complications, and antibiotic resistance
Interviews regarding the adverse events were carried out in all patients. The incidence of adverse events was 6.6% and the drug compliance was 95.1%. Dizziness and headache were the most common adverse events [ Table 3 ].
H. pylori strains were isolated from 17 (73.9%) of the 23 enrolled patients who had undergone endoscopy and bacterial culture in order to check H. pylori status on enrollment. Antibiotic resistance results were amoxicillin (0%), levofloxacin (23.5%), clarythromycin (35.3%), metronidazole (17.6%), and tetracycline (0%).
Univariate analysis showed that none of the clinical factors influenced the efficacy of H. pylori eradication. Only 33% (1/3) of patients with poor compliance showed eradication, while 81% (47/58) with good compliance showed successful eradication [ Table 4 ].
DISCUSSION
The American College of Gastroenterology Guidelines on the Management of H. pylori Infection [19] recommend that rescue therapy should consist of a PPI, quinolone, and amoxicillin as one of the options for second-line H. pylori eradication which has not been previously used. There are a handful of studies in the literature on levofloxacin in second-line treatment, comparing a levofloxacin-containing regimen with the guideline-recommended second-line quadruple therapy. [7] [8] [9] 20, 21] Eradication rates of a levofloxa- cin-containing regimen with treatment duration of 10 days were higher than those of a 7-day treatment course. [22] [23] [24] However, currently available Taiwanese reports in the literature used 7-day quinolone-containing triple therapy. As a result, some physicians still prescribe 7-day regimens in actual clinical practice in Taiwan. The results of current study further emphasized the low ITT and PP results with 7-day quinolone-containing triple therapy. Levofloxacin is a levorotatory isomer of ofloxacin with known activity against many gram-negative and gram-positive bacteria. The mode of action of levofloxacin is based on the inhibition of bacterial DNA topoisomerase II.
[25] The advantages of levofloxacin-containing triple therapy are that there is an in vivo synergistic effect of quinolone antimicrobial agents and PPIs on the strains of H. pylori, [10] and is simple and well tolerated with a high compliance (95.1%) as shown in the present study. The relatively low incidence of adverse events of levofloxacin-containing triple therapy was the key factor to the good compliance.
Poor compliance could be caused by the side effects of medicines and poor understanding of the relations between bad compliance and the risk of developing resistant strains. One of the reasons for the high compliance of 95.1% observed could be the good patient-health care communication status for these registered patients. By doing so, most of these patients, except three, finished all the medications in the present study. However, there was still 66.7% of patients with poor compliance who failed to eradicate H. pylori in the present study.
Antibiotic resistance is one of the important factors for the success of H. pylori eradication. Primary resistance to fluoroquinolones is increasing in many parts of the world. [7] The resistance to levofloxacin in a previous Taiwanese report was 21.2%. [11] The increasing use of quinolones in different countries could be the reason for the increase in resistance to these antibiotics. In the present study, the resistance of levofloxacin was still 23.5%. It is important to realize this issue and the use of levofloxacin should be confined to "rescue" therapy to evade increasing H. pylori resistance toward such an antibiotic. [7] [8] [9] The other important reason for failure in previously mentioned studies could be that the duration of fluoroquinolone-containing therapies was too short. Together, these should explain why the eradication rates of the 7-day levofloxacin-containing triple therapy in Taiwan had dropped below 80%, including the present study, even with an increased dose of 750 mg daily in one study. [15] Cytochrome P450 2C19 (CYP2C19) polymorphism of PPIs could play a role in affecting the eradication of H. pylori. Studies with CYP2C19 slow metabolizers have shown that the combination of a PPI plus amoxicillin (dual therapy) can reliably cure more than 90% of H. pylori infections, especially in Asian populations. [26] [27] [28] [29] Generally, clinicians should prescribe therapeutic regimens that have 90% or greater (grade B level) and probably 95% or greater (grade A level) PP eradication rate to meet the existing practice in the field of other common bacterial infectious diseases. [30] It is therefore concluded that 7-day levofloxacin-containing triple therapy provides an unacceptable PP report card as the second-line H. pylori eradication treatment in Taiwan and should be modified by either extending the duration to 10-14 days or seeking other regimens. 
